Mucosal immunity induced by pneumococcal glycoconjugate

Critical Reviews in Microbiology

Volumn 31, Issue 3, 2005, Pages 137-144

  Lee, Chi Jen ^a,c   Lee, Lucia H ^a   Gu, Xin Xing ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CpG Adjuvant; Mucosal Immunity; Pneumococcal Glycoconjugate

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GLYCOCONJUGATE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; OLIGONUCLEOTIDE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN;

ANTIBODY RESPONSE; CPG ISLAND; DRUG ANTIGENICITY; HOST RESISTANCE; HUMAN; IMMUNIZATION; INTESTINE; LUNG; MUCOSA; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; REVIEW; SPLEEN; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; HUMANS; IMMUNITY, MUCOSAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

PNEUMOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 23744476749     PISSN: 1040841X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408410591005093     Document Type: Review

References (65)

1. Babiuk, L.A., and Tikoo, S.K. 2000. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J. Biotechnol. 83, 105-113.
2. Baldridge, J.R., Yorgensen, Y., Ward, J.R. et al. 2000. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 18, 2416-2425.
3. Beagley, K.W., and Husband, A.J. 1998. Intraepithelial lymphocytes: Origins, distribution, and function. Crit Rev. Immunol. 18, 237-254.
4. Bender, B.S., Rowe, C.A., Taylor, S.F. et al. 1996. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol 70, 6418-6424.
5. Black, S., Shinefield, H., Fireman, B. et al. 2000. Efficacy, safety and Immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19, 187-195.
6. Brandtzaeg, P., Farstad, I.N., Haralssen, G. et al. 2000. Cellular and molecular mechanisms for induction of mucosal immunity. Dev. Biol. Stand. 92, 93-108.
7. Coffman, R.L., Seymour, B.W., Lebman, et al. 1988. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102, 5-28.
8. Cruz, J.R., Gil, L., Cano, F. et al. 1988. Breast milk anti-Escherichia coli heallabile toxin IgA antibodies protect against toxin-induced infantile diarrhea. Acta Paediatr. Scand. 77, 658-662.
9. Czerkinsky, C., Holmgren, J. 1995. The mucosal immune system and prospects for anti-infectious and anti-inflammatory vaccine. Immunologist 3, 97-103.
10. Davis, H.L., Weeranta, L.R., Waldschmidt, T.J. et al. 1998. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876.
11. De Hann, L., Holtrop, M., Verweij, W.R. et al. 1999. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin. Immunology 97, 706-713.
12. Ey, P.L., Russell-Jones, G.L., and Jenkin, C.R. 1980. Isotypes of mouse IgG-1. Evidence for "non-complement-fixing" IgG1 antibodies and characterization of their capacity to interfere with IgG2 sensitization of target red blood cells for lysis by complement. Mol. Immunol. 17, 699-710.
13. Freytag, L.C., and Clements, J.D. 1999. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236, 215-236.
14. Fujihashi, K., Koga, R., van Ginkel, F. W. et al. 2002. A dilemma for mucosal vaccination: Efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20 (19-20), 2431-2438.
15. Gay, N., Ramsay, M., and Waight, P. 1999. Rotavirus vaccination and intussusception. Lancet 354, 956.
16. Giebink, G.S. 1985. Preventing pneumococcal diseases in children: Recommendation for using pneumococcal vaccines. Pediatr. Infect. Dis. J. 4, 343-348.
17. Giebink, G.S. 1989. The microbiology of otitis media. Pediatr. Infect Dis. J. 8, 18-20.
18. Greenspan, N.S., and Cooper, L.J.N. 1992. Intermolecualr cooperativity: A clue to why mice have IgG3? Immunol. Today 13, 164-168.
19. Gruber, W.C. 2002. The role of live influenza vaccines in children. Vaccine 20 (Suppl 2), S66-S73.
20. Haan, L., Verweij, W.R., Holtrop, M. et al. 2001. Nasal or intramuscular immunization of mice with influenzae subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 19, 2898-2907.
21. Hemmi, H., Takeuchi, O., Kawai, T. et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745.
22. Horner, A.A., and Raz, E. 2000. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant. Clin. Immunol. 95, S19-S29.
23. Hou, Y., Hu, W.G., Hirano, T. et al. 2002. A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine 20, 2375-2381.
24. Jakobsen, H., and Jonsdottir, I. 2003. Mucosal vaccination against encapsulated respiratory bacteria-New potentials for conjugate vaccines? Scand. J. Immunol. 58(2), 119-139.
25. Janeway, C.A. Jr., and Mcdzhitov, R. 1998. Introduction: The role of innate immunity in the adaptive immune response. Semin. Immunol. 10(5), 349-350.
26. Katial, R.K., Brandt, B.L., Moran, E.E. et al. 2002. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 70(2), 702-707.
27. Kelsall, B.L., and Strober, W. 1996. Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J. Exptl. Med. 183, 237-247.
28. Krieg, A.M., Hartmann, G., and Yi, A.K. 2000. Mechanism of action of CpG DNA. Curr. Top. Microbiol. Immunol. 247, 1-21.
29. Krieg, A.M., Yi, A.K., Matson, T.J. et al. 1995. CpG motifs in bacterial DNA trigger direct B cell activation. Nature 374, 546-549.
30. Lee, C.J. Advances in pneumococcal vaccines. 1999. Infect. Med. 16(9), 596-612.
31. Lee, C.J., Lee, L.H., and Frasch, C.E. 2003. Protective immunity of pneumococcal glycoconjugates. Crit. Rev. Microbiol. 29(4), 1-17.
32. Lee, C.J., Wang, T.R., and Frasch, C.E. 2001. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers. Vaccine 19, 3216-3225.
33. Lycke, N. 1997. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148, 504-520.
34. Lycke, N., Tsuji, T., and Holmgren, J. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22, 2277-2281.
35. McCluskie, M.J., and Davis, H.L. 1999. CpG DNA as mucosal adjuvant. Vaccine 18, 231-237.
36. McCluskie, M.J., Weeratna, R.D., and Davis, H.L. 2000. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol. Med. 6, 867-877.
37. McCluskie, M.J., Weeratna, R.D., Payette, P.J. et al. 2001. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit. Rev. Immunol. 21, 103-120.
38. McKenzie, B.S., Brady J.L., and Lew, A.M. 2004. Mucosal immunity: Overcoming the barrier for induction of proximal responses. Immunol. Res. 30(1), 35-71.
39. McNeal, M.M., Rae, M.N., Conner, M.E. et al. 1998. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology 243, 158-166.
40. Mendelman, P.M., Cordova, J., and Cho, I. 2001. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 19, 2221-2226.
41. Mowat, A.M., Donachie, A.M., Jagewall, S. et al. 2001. CTA1-DD-immune stimulating complexes: A novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J. Immunol. 167, 3398-3405.
42. Olszewska, W., Partidos, C.D., and Steward, M.W. 2000. Antipeptide antibody responses following intranasal immunization: Effectiveness of mucosal adjuvants. Infect. Immun. 68, 4923-4929.
43. Owen, R.L. 1999. Uptake and transport of intestinal macromolecules and microorganisms by M cells in Peyer's patches: A personal and historical perspective. Semin. Immunol. 11, 157-163.
44. Pankow, W., von Wiehert, P. 1988. M cell in the immune system of the lung. Respiration 54, 209-219.
45. Pizza, M., Giuliani, M.M., Fontana, M.R. et al. 2001. Mucosal vaccines: Non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 2534-2541.
46. Rappuoli, R., Douce, G., Dougan, G. et al. 1995. Genetic detoxification of bacterial toxins: A new approach to vaccine development. Int. Arch. Allergy Immunol. 108, 327-333.
47. Robbins, J.B., Schneerson, R., and Szu, S.C. 1995. Perspective hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171, 1387-1398.
48. Roos, A., Bouwman, L.H., van Gijlswijk-Janssen, D.J. et al. 2001. Human IgA activates the complement system via the mannan-binding lectin pathway. J. Immunol. 167, 2861-2868.
49. Russell, M.W., and Mansa, B. 1989. Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound, IgA. Scand. J. Immunol. 30, 175-183.
50. Sasaki, S., Hamajima, K., Fukushima, J. et al. 1998. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophospharyl lipid A adjuvant vaccine. Infect. Immun. 66, 823-826.
51. Sasaki, S., Sumino, K., Mamajima, K. et al. 1998. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol 72, 4931-4939.
52. Seong, S.Y., Cho, N.H., Kwon, I.C. et al. 1999. Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect. Immun. 67, 3587-3592.
53. Simmons, C.P., Ghaem-Magami, M., Petrovska, L. et al. 2001. Immunomodulation using bacterial enterotoxins. Scand. J. Immunol. 53, 218-226.
54. Singh, M., and O'Hagan, D. 1999. Advances in vaccine adjuvants. Nat. Biotechnol. 17, 1075-1081.
55. Sisk, J.E., Moskowitz, A.J., Whang, W. et al. 1997. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278, 1333-1339.
56. Sonoda, E., Matsumoto, R., Hitoshi, Y. et al. 1989. Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J. Exptl. Med. 170, 1415-1420.
57. Staats, H.F., Jackson, R.J., Marinaro, M. et al. 1994. Mucosal immunity to infection with implications for vaccine development. Curr. Opin. Immun. 6, 572-583.
58. Steinmertz, I. 1997. Comparative in vivo analysis of IgA- and IgG-mediated mucosal defense against bacterial pathogens. Behring Inst. Mitt. 98, 53-55.
59. Toumanen, E.I., Austrian, R., and Masure, H.R. 1995. Pathogenesis of pneumococcal infection. N. Eng. J. Med. 11, 1280-1284.
60. Unkeless, J.C., Selgliano, E., Freedman, V.H. 1988. Structure and function of human and murine receptors for TgG. Annu. Rev. Immunol. 6, 251-281.
61. Verweij, W.R., de Haan, L., Holtrop, M. et al. 1998. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenzae virus surface antigen. Vaccine 16, 2069-2076.
62. Vidarsson, G., Jonsdottir, G., Jonsson, S. et al. 1994. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J. Infect. Dis. 170, 592-599.
63. Von Hunolstein, C., Mariotti, S., Teloni, R. et al. 2001. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient antipolysaccharide and anti-carrier polyvalent vaccines. Vaccine 19, 3058-3066.
64. Watson, D.A., Musher, D.M., and Verhoef, J. 1995. Pneumococcal virulence factors and host immune responses to them. Eur. J. Clin. Microbiol. Infect. Dis. 14, 479-490.
65. Weeratna, R.D., McCluskie, M.J., Xu, Y. et al. 2000. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18, 1755-1762.